



1 more

1646--

PATENT
Attorney Reference Number 4239-66645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere *et al.*

Application No. 10/700,313

Filed: October 31, 2003

Confirmation No.

For: CC CHEMOKINE RECEPTOR 5 DNA,
NEW ANIMAL MODELS AND
THERAPEUTIC AGENTS FOR HIV
INFECTION

Examiner: John D. Ulm

Art Unit: 1646

Attorney Reference No. 4239-66645

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed February 27, 2004

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and two of the references cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



11:dv 02/27/04 4239-66645

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere *et al.*

Application No. 10/700,313

Filed: October 31, 2003

Confirmation No.

For: CC CHEMOKINE RECEPTOR 5 DNA,
NEW ANIMAL MODELS AND
THERAPEUTIC AGENTS FOR HIV
INFECTION

Examiner: John D. Ulm

Art Unit: 1646

Attorney Reference No. 4239-66645

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Date Mailed February 27, 2004

**INFORMATION DISCLOSURE STATEMENT
FOR CONTINUING APPLICATIONS**

Listed on the accompanying form PTO-1449 are several English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 08/864,458, which was filed May 28, 1997, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application. Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.

Copies of documents listed on the accompanying form PTO-1449 that were cited by the Patent Office in the earlier application are enclosed. Also enclosed are copies of any documents not previously submitted in this application.


Applicants are filing this Information Disclosure Statement ("IDS") before the mailing of a first Office action after that filing. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | |
|-------------------------------|------------------|
| Attorney Docket Number | 4239-66645 |
| Application Number | 10/700,313 |
| Filing Date | October 31, 2003 |
| First Named Inventor | Combadiere |
| Art Unit | 1646 |
| Examiner Name | John D. Ulm |

U.S. PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Number | Date | Name |
|-------------------------|------------------------|----------------|---------------|----------------------------|
| | | US2001/0000241 | 12 April 2001 | Li <i>et al.</i> |
| | | US2002/0076745 | 20 June 2002 | Li <i>et al.</i> |
| | | US2002/0099176 | 25 July 2002 | Li <i>et al.</i> |
| | | US2002/0106742 | 08 Aug 2002 | Samson <i>et al.</i> |
| | | US2002/0110805 | 15 Aug 2002 | Samson <i>et al.</i> |
| | | US2002/0110870 | 15 Aug 2002 | Samson <i>et al.</i> |
| | | US2002/0132269 | 19 Sept 2002 | Li <i>et al.</i> |
| | | US2002/0150888 | 17 Oct 2002 | Gray <i>et al.</i> |
| | | US2003/0023044 | 30 Jan 2003 | Li <i>et al.</i> |
| | | 5,440,021 | 08 Aug 1995 | Chuntharapai <i>et al.</i> |
| | | 6,025,154 | 15 Feb 2000 | Li and Ruben |
| | | 6,265,184 | 24 July 2001 | Gray <i>et al.</i> |
| | | 6,268,477 | 31 July 2001 | Gray <i>et al.</i> |
| | | 6,448,375 | 10 Sept 2002 | Samson <i>et al.</i> |
| | | 6,511,826 | 28 Jan 2003 | Li <i>et al.</i> |
| | | 6,528,625 | 04 Mar 2003 | Wu <i>et al.</i> |
| | | | | |

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

| | |
|-------------------------------|------------------|
| Attorney Docket Number | 4239-66645 |
| Application Number | 10/700,313 |
| Filing Date | October 31, 2003 |
| First Named Inventor | Combadiere |
| Art Unit | 1646 |
| Examiner Name | John D. Ulm |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Number | Date | Country |
|-------------------------|------------------------|-------------|--------------|---------|
| | | 2,146,328 | 26 May 1994 | Canada |
| | | WO 94/12635 | 09 June 1994 | WIPO |
| | | WO 95/19436 | 20 July 1995 | WIPO |
| | | WO 96/39437 | 12 Dec 1996 | WIPO |
| | | WO 97/22698 | 26 June 1997 | WIPO |
| | | WO 97/32019 | 04 Sept 1997 | WIPO |
| | | WO 97/37005 | 09 Oct 1997 | WIPO |
| | | WO 97/44055 | 27 Nov 1997 | WIPO |
| | | WO 97/47318 | 18 Dec 1997 | WIPO |

| Examiner's Initials* | Cite No. (optional) | OTHER DOCUMENTS |
|-------------------------|------------------------|---|
| | | Alkhatib <i>et al.</i> , "CC CKR5: A RANTES, MIP-1 α , MIP-1 β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1," <i>Science</i> , 272:1955-1958, June 28, 1996 |
| | | Arenzana-Selsdedos <i>et al.</i> , "HIV blocked by chemokine antagonist," <i>Nature</i> 383:400, October 3, 1996 |
| | | Aversa <i>et al.</i> , "An Interleukin 4 (IL-4) Mutant Protein Inhibits both IL-4 or IL-13-induced Human Immunoglobulin G4 (IgG4) and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors," <i>J. Exp. Med.</i> , 178: 2213-2218, December 1993 |
| | | Carroll <i>et al.</i> , "Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells," <i>Science</i> 276:273-276, April 11, 1997 |

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number 4239-66645

Application Number 10/700,313

Filing Date October 31, 2003

First Named Inventor Combadiere

Art Unit 1646

Examiner Name John D. Ulm

| | | |
|--|--|---|
| | | Cocchi <i>et al.</i> , "Identification of RANTES, MIP-1 α , and MIP-1 β as the Major HIV-Suppressive Factors Produced by CD8 ⁺ T Cells," <i>Science</i> , 270: 1811-1815, December 15, 1995 |
| | | Combadiere and Murphy, "Cloning and Functional Expression of a Human Monocyte CC Chemokine Receptor," <i>The American Society for Cell Biology</i> , Abstract; Submitted to 1995 Annual Meeting no later than August 1, 1995 |
| | | Combadiere <i>et al.</i> , "Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 α , MIP-1 β , and RANTES," <i>J. Leuk. Biol.</i> 60:147-152, July 1996 |
| | | Combadiere and Murphy, "Cloning and Functional Expression of Two Human Monocyte CC Chemokine Receptors," <i>The American Society for Biochemistry and Molecular Biology</i> , Abstract, submitted to 1996 Annual Meeting no later than January 30, 1996 |
| | | Combadiere <i>et al.</i> "Cloning, Chromosomal Localization, and RNA Expression of a Human β Chemokine Receptor-Like Gene," <i>DNA and Cell Biol.</i> , 14(8):673-680, November 8, 1995 |
| | | He <i>et al.</i> , "CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia," <i>Nature</i> 385:645-649, February 13, 1997 |
| | | Kaplan <i>et al.</i> , "Chemokines and the allergic response," <i>Exp. Dermatol.</i> , 4(4 Pt 2):260-265, August 1995 (ABSTRACT ONLY) |
| | | Margolis <i>et al.</i> , "Host vs. Viral Factors in Human Tissues Infected In Vitro with HIV-1," <i>Mol. Path. Model</i> April 11, 1997 |
| | | McKenzie <i>et al.</i> , "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3735-3739, April 1993 |
| | | Minty <i>et al.</i> , "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses," <i>Nature</i> , 362:248-250, March 18, 1993 |
| | | Raport <i>et al.</i> "Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1 β , and MIP-1 α ," <i>J. Biol. Chem.</i> , 271(29):17161-17166, July 19, 1996 |
| | | Robinson <i>et al.</i> , "Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells," <i>Clin. Exp. Immunol.</i> , 101(3):398-407, September 1995 (ABSTRACT ONLY) |
| | | Samson <i>et al.</i> , "Molecular Cloning and Functional Expression of a New Human CC-Chemokine Receptor Gene," <i>Biochem.</i> , 35(11):3362-3367, March 1996 |

**EXAMINER
SIGNATURE:**

**DATE
CONSIDERED:**

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number 4239-66645

Application Number 10/700,313

Filing Date October 31, 2003

First Named Inventor Combadiere

Art Unit 1646

Examiner Name John D. Ulm

Simmons *et al.*, "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist," *Science* 276:276-279, April 11, 1997

Uguccioni *et al.*, "Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes," *Eur. J. Immunol.*, 25(1):64-68, January 1995 (ABSTRACT ONLY)

Zimmerman *et al.*, "Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk," *Mol. Med.* 3(1):23-36, January 1997

Zurawski *et al.*, "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction," *EMBO J.*, 12(7):2663-2670, 1993

**EXAMINER
SIGNATURE:**

**DATE
CONSIDERED:**

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.